Does the benefit of optimal MASH treatment depend on a reduction in myosteatosis?

Clin Res Hepatol Gastroenterol

Service d'Hépato-Gastroentérologie, Cliniques universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium; Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique, UCLouvain, 1200 Brussels, Belgium. Electronic address:

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The muscle-liver axis, well known in cirrhosis, is also important in the multisystem disease known as metabolic dysfunction-associated steatohepatitis (MASH). The convincing results obtained with a triple peroxisome proliferator-activated receptor (PPAR) agonist in this setting confirm this hypothesis, demonstrating a beneficial effect not only on the severity of MASH in terms of steatosis, inflammation and fibrosis, but also in terms of hepatic and muscle insulin sensitivity. The pathophysiology of MASH and mechanism of action of triple PPAR agonist suggest that this may be related to improved lipid management in skeletal muscles and highlights the importance of studying the muscle-adipose tissue-liver axis in the management of MASH.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2025.102640DOI Listing

Publication Analysis

Top Keywords

ppar agonist
8
mash
5
benefit optimal
4
optimal mash
4
mash treatment
4
treatment depend
4
depend reduction
4
reduction myosteatosis?
4
myosteatosis? muscle-liver
4
muscle-liver axis
4

Similar Publications

Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC.

View Article and Find Full Text PDF

Neurocognitive disorders represent a significant global health challenge and are characterized by progressive cognitive decline across conditions including Alzheimer's disease, mild cognitive impairment, and diabetes-related cognitive impairment. The hippocampus is essential for learning and memory and requires intact neuroplasticity to maintain cognitive function. Recent evidence has identified the brain insulin signaling pathway as a key regulator of hippocampal neuroplasticity through multiple cellular processes including synaptic plasticity, neurotransmitter regulation, and neuronal survival.

View Article and Find Full Text PDF

Background: Managing patients with primary biliary cholangitis (PBC) who demonstrate an inadequate response to ursodeoxycholic acid or experience intolerable side effects remains a significant clinical challenge.

Objectives: This study aims to investigate the efficacy and safety of peroxisome proliferator-activated receptor (PPAR) agonists in the treatment of PBC.

Design: Meta-analysis and systematic review.

View Article and Find Full Text PDF

In Vivo, Ex Vivo, and In Vitro Antihyperglycemic Evaluation of Croton ehrenbergii.

Planta Med

September 2025

Centro de Investigaciones Químicas, IICBA, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México.

Various species have been traditionally used to treat diabetes; however, the antidiabetic potential and safety of many of these species remain poorly understood. This study evaluated the chemical composition, antihyperglycemic activity, insulin-sensitizing effect, and acute oral toxicity of . Dichloromethane, ethyl acetate, -butanol, and aqueous residue fractions were obtained via liquid-liquid extraction from the hydroalcoholic extract obtained via maceration of the aerial parts.

View Article and Find Full Text PDF

[Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options].

Inn Med (Heidelb)

September 2025

Bereich Hepatologie, Medizinische Klinik II, Universitätsklinikum Leipzig, Leipzig, Deutschland.

Primary biliary cholangitis (PBC) is a chronic inflammatory, autoimmune-mediated liver disease that progresses to fibrosis and cirrhosis if left untreated. In addition to preventing complications, the management of burdensome symptoms, particularly pruritus, represents a key therapeutic goal. Ursodeoxycholic acid (UDCA) is the established first-line treatment; however, up to 40% of patients show an inadequate response and require second-line treatment.

View Article and Find Full Text PDF